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The recurrence of new human cases of Middle East respiratory syndrome coronavirus (MERS-CoV) 
underscores the need for effective therapeutic countermeasures. Nonhuman primate models are 
considered the gold standard for preclinical evaluation of therapeutic countermeasures. However, 
MERS-CoV-induced severe respiratory disease in humans is associated with high viral loads in the lower 
respiratory tract, which may be difficult to achieve in nonhuman primate models. Considering this 
limitation, we wanted to ascertain the effectiveness of using a MERS-CoV infectious clone (icMERS-0) 
previously shown to replicate to higher titers than the wild-type EMC 2012 strain. We observed 
respiratory disease resulting from exposure to the icMERS-0 strain as measured by CT in rhesus 
monkeys with concomitant detection of virus antigen by immunohistochemistry. Overall, respiratory 
disease was mild and transient, resolving by day 30 post-infection. Although pulmonary disease was 
mild, these results demonstrate for the first time the utility of CT imaging to measure disease elicited by 
a MERS-CoV infectious clone system in nonhuman primate models.
Emerging in 2012, Middle East respiratory syndrome coronavirus (MERS-CoV) continues to be a threat to global 
human health. Twenty-seven countries have reported human cases of MERS-CoV, with all cases occurring in 
individuals returning from travel to the Arabian Peninsula or having contact with someone returning from the 
Arabian Peninsula (http://www.who.int/emergencies/mers-cov/en/). In May 2015, a single individual returning 
from travel to the Arabian Peninsula initiated an epidemic in South Korea that infected 186 people, and resulted 
in ~20% mortality1. Since January 2017, countries within the Arabian Peninsula reported monthly cases of 
MERS-CoV originating from either human contact with an infected individual or contact with dromedary cam-
els, considered an intermediate zoonotic host (http://www.cidrap.umn.edu/). Infected individuals typically pres-
ent with respiratory symptoms that can progress to severe pulmonary disease that is associated with a mortality 
rate of ~35% of reported cases1. Despite the threat to global public health, prevention of human-to-human trans-
mission continues to rely upon standard public healthcare practices, and oxygen supplementation and mechanical 
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respiratory support for infected individuals experiencing severe pulmonary complications1. Anti-MERS thera-
peutic and vaccine countermeasures are gradually advancing toward the clinic (reviewed in1); however, effective 
evaluation of anti-MERS countermeasures has been hampered, until recently, by the availability of animal models 
that reflect severe pulmonary complications observed during human infections2,3.
The approximate incubation period of MERS is 5 days (range 2–14 days), patients presenting with overt dis-
ease develop a fever, cough and shortness of breath. Severe pulmonary disease in humans has been associated 
with the detection of high viral loads in tracheal aspirates, sputum, throat swab, and blood or serum4,5. Recovery 
from severe respiratory disease may be associated with antibody and T cell responses6. The only publicly available 
autopsy report indicates lower respiratory tract (LRT) infection and a resulting pneumonia7,8. X-ray radiography 
and CT of patients also indicates a LRT disease in which pneumonia is the prominent finding (reviewed in1). 
Viral loads are highest in tracheal aspirates, which may contain increased material from the LRT based on ciliary 
motion. Therefore, an animal model that achieves pneumonia, and high viral loads in the trachea and lower res-
piratory tract (LRT) are important aspects to fully recapitulate severe human disease.
Three different research groups established models for MERS-CoV infection in two non-human primates 
(NHPs), the rhesus macaque and common marmoset9–15. Infection of the LRT could be established using differ-
ent invasive strategies for placement of the challenge material9,11,15. The range of clinical outcomes included mild 
respiratory disease detectable using computed tomography and radiographic imaging9,11,15, to severe respiratory 
disease producing clinical endpoints indicative of a fatal disease that required euthanasia in two common mar-
moset models9,15. Two groups observed lethal disease following intratracheal, intranasal, and ocular exposure 
with the MERS-EMC isolate. However, Chan et al. indicate that lethality could be due to manipulations of mar-
mosets, which are less hardy than macaque species9. A third group observed mild to moderate disease, but used 
higher viral titer, the MERS-Jordan isolate and a single route of challenge11. Experiments in which rhesus mon-
keys were used indicated that rhesus develop transient disease that peaks between day 3 and 5 post-infection and 
clears by day 14 post-infection10, however, gross and histopathology was not collected at peak of disease. Viral 
load peaks in this period in both marmosets and rhesus, and models in which subjects are euthanized at these 
early time points in disease progression have been used to demonstrate antiviral efficacy by measuring differences 
in viral load16,17. Overall, these disparate clinical outcomes indicate that the human strains of MERS-CoV used in 
the studies (EMC 2012 and Jordan) may not be suitably adapted to NHPs, thereby making it difficult for routine 
establishment of high viral loads in the LRT.
Understanding that it may be difficult to establish infection in NHPs with wild-type human MERS-CoV 
strains, we investigated the use of a novel MERS-CoV infectious clone. In previous studies, the MERS-0 infectious 
clone (icMERS-0) exhibited enhanced replication kinetics and higher titers than an EMC 2012 infectious clone 
on monkey kidney cells, and replicated to 10-fold higher titers than EMC 2012 in the lungs of infected mice2. The 
enhanced replication profile made icMERS-0 an attractive option for establishing infection in the rhesus macaque 
model. Intratracheal exposure of icMERS-0 elicited radiological and pathological signs of mild respiratory dis-
ease in the rhesus macaque. This is the first study demonstrating the capacity of a MERS-CoV infectious clone to 
elicit signs of respiratory disease in a NHP model. The work presented here expands the utility of the MERS-CoV 
reverse genetics systems for use in NHP models.
Results
The icMERS-0 virus originates from the EMC 2012 genomic sequence and contains an additional insertion of 
three amino acids followed by a single amino acid change (S885L) in the S2 region of the spike gene, which aug-
ment replication2. The icMERS-0 virus was evaluated in six rhesus macaques that were survivors from a prior 
Ebola countermeasure efficacy experiment (Supplemental Fig. 1 for individual information). All six rhesus mon-
keys were infected with a target dose of 5 × 106 PFU of icMERS-0 by intratracheal inoculation, with the entire 
dose of 6.62log10 PFU/mL placed at the carina. Rhesus monkeys were randomly assigned to two separate groups: 
an early time point group (day 5 post-infection) to examine pathology at peak disease (NHP3, NHP5, & NHP6) 
and a late time point group (day 30 post-infection) to monitor disease progression (NHP1, NHP2, & NHP4). All 
clinical signs (O2 saturation and temperature) remained within normal range throughout the entire experiment 
(Fig. 1). In accordance with clinical signs, complete blood counts with differential and serum chemistry analytes 
did not exhibit clinically significant changes from animal baselines (data not shown).
Computed Tomography indicates that MERS-0 elicits mild respiratory disease. Computed 
tomography (CT) imaging is a highly sensitive technique for evaluating tissues for pathological alterations. 
Pulmonary pathological changes can be quantified by measuring the intensity of hyperdense voxels in the 
total lung volume over the course of disease, also referred to as percent change in lung hyperdensity (PCLH)18. 
Areas of hyperdensity represent changes in lung tissue associated with lung pathology. NHP1 exhibited obvious 
increases in PCLH at days 3, with gradual resolution through day 30 post-infection (Fig. 2a). With the exception 
of NHP5, increases in PCLH were readily detectable over baseline in all NHPs over the course of disease (Fig. 2b). 
NHP5 exhibited no change in PCLH through the course of the experiment. NHP1, NHP3, NHP4, and NHP6 
experienced increases that were above what was observed in prior NHP infections with wild-type MERS-CoV 
strains. It must be noted that improper endotracheal tube placement in NHP6 artificially exaggerated lung dis-
ease during the day 5 imaging session. Quantitative measurement of hyperdense regions indicate a peak at day 3 
post-infection (p.i.) for NHPs that developed multifocal lung pathology which gradually resolved through day 30 
p.i. (Fig. 2b). Nevertheless, CT demonstrates that icMERS-0 exposure resulted in quantifiable increases in lung
pathology that were more severe than that previously observed with wild-type human strains10,11. Notably, disease
in rhesus monkeys constitutes a mild respiratory infection compared to PCLH recalculated from data obtained 
from a previous study following infection with EMC 201211 (Supplemental Fig. 2).
Transient, mild pulmonary pathology in rhesus monkeys after MERS-0 inoculation. Grossly, 
all 3 animals (NHP3, 5 and 6) euthanized at day 5 post-inoculation (pi) had diffuse, mild pulmonary conges-
tion (Fig. 3a). Histologically, these 3 animals had focal-to-diffuse, minimal-to-mild interstitial pneumonia. The 
alveoli were lined by hyperplastic type II pneumocytes and filled with fibrin, edema, red blood cells, and mac-
rophages. The septa were minimally-to-mildly expanded by fibrin, proteinaceous fluid, and mononuclear cells 
(Fig. 3b). Multifocally, other alveoli were often expanded and filled with eosinophilic, fibrillar material. The septa 
showed minimal to mild smooth muscle cell hyperplasia, fibrosis and vascular congestion (Fig. 3c). The three 
animals (NHP1, 2, and 4) necropsied on day 30 p.i. showed no significant lung lesions (Fig. 3d). Quantitation of 
microscopic findings in the lung are commensurate with histopathological findings (Supplemental Table 1), while 
extrapulmonary tissues exhibited Incidental histological changes (Supplemental Tables 2 and 3).
Immunohistochemistry of MERS spike protein in the lungs. A scarce number of pneumocytes, 
perivascular inflammatory cells (Fig. 4a), epithelial cells of submucosal glands, and lymphoid aggregates (Fig. 4b) 
were positive for MERS spike protein in all 3 animals (NHP3, 5 and 6) euthanized at day 5 pi. In the lungs of 3 
animals (NHP1, 2 and 4) at day 30 pi, more epithelial cells of submucosal glands in the bronchi and few cells in 
the BALTs were positive for MERS spike antigen (Fig. 4c). Dual immunohistochemistry staining for MERS spike 
and CD26 demonstrated MERS positivity in CD26 positive cells for all 3 subjects on day 5 pi and all three subjects 
Figure 1. Temperature and arterial O2 saturation. (a) Study animals did not develop fever or deviate outside of 
normal macaque temperature ranges. (b) Animals did not exhibit O2 saturation loss outside of normal macaque 
ranges. Normal ranges are depicted in beige.
Figure 2. Percent change in lung hyperdensity (PCLH). (a) Representative lung field (b) Lung consolidation 
depicted as the percentage of the volume of hyperdense voxels in the total lung volume for each icMERS virus 
exposed animal. *Day 5 for NHP6 was omitted due to improper endotracheal tube intubation for the imaging 
breadth hold. Solid and dotted black lines indicate the baseline mean and 3 SD range of the hyperdense volume 
from ic-MERS-0 exposed animals included in this study. Dotted red lines indicate the upper and lower method 
range limits of MERS exposed rhesus monkeys (n = 33).
Figure 3. Pulmonary pathology in rhesus macaques inoculated with MERS-0. (a) Diffuse, mild pulmonary 
congestion. NHP3 at day 5 of MERS post-inoculation. (b) Multifocal, mild interstitial pneumonia characterized 
by type II pneumocyte hyperplasia and alveolar edema, fibrin and hemorrhage. NHP6 at day 5 of MERS post-
inoculation. HE; (c) Multifocal alveolar emphysema containing small amount of eosinophilic to basophilic 
fibrillary material. NHP6 at day 5 of MERS post-inoculation. HE. (d) Day 30 H&E of lung demonstrating 
clearance of proteinaceous material and resolution of mild interstitial pneumonia.
Figure 4. Immunohistochemistry of MERS spike protein in the lung. (a) Rare MERS spike antigen positive 
pneumocytes (arrows) of NHP6 at day 5 pi. (b) Rare MERS spike antigen positive cells in the submucosal glands 
(arrow) and lymphoid aggregates (^) of NHP6 at day 5 pi; (c) Many epithelial cells (arrow) of submucosal 
glands in the bronchi and fewer cells in the BALTs (^) were positive for MERS spike antigen of NHP2 at day 30 
pi. (d) Increased numbers of alveolar macrophages that are positive for CD26 and MERS-CoV on day 5 pi. (e) 
Reduced hyperplasia and fewer CD26+ cells and alveolar macrophages were present on day 30 pi.
were negative at 30 days post-infection (Fig. 4d,e). Relatively, alveolar macrophages were more prominent on day 
5 pi than at day 30 pi. In contrast, epithelial cells of submucosal glands had more icMERS-0 antigen positive cells 
in 30 dpi group than the 5 dpi group. The small number of antigen positive cells increases the opportunity for 
error during lower lung aspirate sampling for RNA analysis, and may account for our inability to detect MERS 
viral RNA by qRT-PCR in lung aspirates (Supplemental Table 4). By focusing the RNA isolation on samples pre-
viously identified to be positive by IHC, icMERS-0 was detected in formalin-fixed, paraffin-embedded (FFPE) 
lung tissues (Table 1). The leader-ORF1 primer set detects full-length genomic and subgenomic RNAs, whereas 
the leader-ORFN combination detects subgenomic, replicating RNAs in infected cells. Subgenomic RNAs were 
detected in the 5 dpi group, but not in the 30 dpi group, indicative of higher levels of infection at 5 dpi (Table 1). 
Nonetheless, detection of icMERS-0 RNA in the 30 dpi group may be indicative of a viral adaptation and possible 
replication, but further studies would be required to confirm this hypothesis.
Discussion
In this experiment, we have demonstrated that the icMERS-0 infectious clone derived from MERS-CoV is more 
pathogenic than the wild-type MERS-CoV Jordan isolate used in previous rhesus experiments. We have also 
demonstrated that disease elicited by icMERS-0 infection of rhesus peaked at D3–D5 post-exposure and resolves 
by D30 post-exposure. Infection corresponded with enhanced numbers of alveolar macrophages identified at 
D5 post-exposure, relative to day 30 post-exposure; similar to data previously reported for the rhesus macaque 
model13,14. The data further supports that the available MERS-CoV NHP models do not recapitulate human dis-
ease and that adaptation of MERS-CoV to NHPs may provide a suitable NHP model.
In the absence of an NHP model that reflects severe pulmonary disease with measurable clinical endpoints, hav-
ing a noninvasive method for quantifying MERS-CoV-induced lung disease is important. Previous studies from our 
group demonstrate that the kinetics of MERS-CoV-induced mild lung disease can be readily measured using CT 
imaging combined with quantitation of the PCLH10. A previous study with MERS-CoV Jordan strain in the rhesus 
model established a range of values for PCLH analysis10. In the current study, icMERS-0 strain exhibited an increase 
in PCLH in 50% of the animals compared to that obtained with the Jordan strain from the prior rhesus study. 
Enhanced PCLH indicates that icMERS-0 may exhibit augmented pathogenesis compared to wild-type strains in 
the rhesus model; albeit additional studies directly comparing icMERS-0 to wild-type strains would be benefi-
cial. Despite enhanced pathogenesis with icMERS-0, disease can be considered mild compared to the PCLH levels 
achieved in a rhesus model for smallpox utilizing cowpox virus19,20. PCLH levels are 10–80 fold higher in the rhesus 
smallpox model and are commensurate with overt signs of severe respiratory disease and mortality. These disparate 
outcomes in pulmonary disease severity indicate that MERS-CoV may not be adapted to overcome host immune 
mechanisms that preclude MERS-CoV pathogenesis in the rhesus model. Two approaches may facilitate develop-
ment of models that reproducibly recapitulate human MERS-CoV pathogenesis: (i) alter the NHP host to one that 
is more susceptible to MERS-CoV infection and pathogenesis; or, (ii) adapt MERS-CoV in the rhesus model.
The common marmoset may be a more tractable NHP model for investigating MERS-CoV. More severe res-
piratory disease in the marmoset model, compared to the rhesus model, is reproducibly observed among all 
groups that have developed both pathogenic NHP models for MERS-CoV9,11,15. Two groups reported severe 
respiratory disease in the marmoset with clinical endpoint criteria indicative of a lethal disease requiring eutha-
nasia9,15. In a third study the Jordan and EMC 2012 wild-type MERS-CoV strains exhibited large increases in the 
volume of lung tissue with pathological change, measured from CT images11. Direct quantitative comparisons 
of lesion volumes between rhesus and marmosets is complicated by differences in the animal lung volumes and 
the rapid breathing rate of marmosets compared to rhesus. Nonetheless, we were able to utilize data previously 
obtained following infection of marmosets with EMC 2012 to calculate the PCLH levels in a manner similar to 
that obtained for the rhesus monkeys (Supplemental Fig. 2). The higher PCLH levels in the marmosets indicate 
Sample Day PE
Lung Sample Ct Values
ORF1 ORFN 18S
DFLD – Lung R. Caudal 30 35.72 N 16.44
DFLD – Lung L. Cranial 30 N N 16.22
DFBGA – Lung R. Caudal 5 37.02 37.22* 17.26
DFBGA – Lung L. Cranial 5 36.29 N 17.45
O5M – Lung R. Caudal 30 37.40 N 15.96
O5M – Lung L. Cranial 30 40.00 N 16.33
PH1071 – Lung R. Caudal 5 36.69* N 17.78
PH1071 – Lung L. Cranial 5 36.75 34.17 17.52
DFCX – Lung R. Caudal 30 39.24 N 15.82
DFCX – Lung L. Caudal 30 N N 16.05
A6V091 – Lung R Caudal 5 36.10 N 17.75
A6V091 – Lung L Caudal 5 32.24 31.19 17.44
A6V091 – Negative Control (Lung Aspirate) 5 N N 10.32
A6V091 – Negative Control (Lung Aspirate) 5 N N 10.71
Table 1. icMERS-0 RNA from FFPE lung tissue. Ct values represent an average of duplicate samples. N is none 
detected. *Represents a single value obtained for duplicate samples.
that more effective disease can be achieved in the marmosets. Accordingly, we propose that the icMERS-0 strain 
may elicit more severe respiratory disease in the marmoset model than that observed in the current study.
Technical differences that facilitate effective delivery of virus in the marmoset model, host genetic variation in 
the marmoset that facilitate infection, or host genetic variation in the rhesus macaque that curb infection may all 
contribute to differences in virulence observed between the two models. Since it is difficult to control for varia-
tion in host genetics in outbred NHP model systems, adapting MERS-CoV in the rhesus model may be a feasible 
option to circumvent these obstacles. The availability of animals and known reagents increase the feasibility and 
further enhance the attractiveness of the rhesus model. Regardless, proposed experiments should meet recom-
mendations under the potential pandemic pathogen care and oversight (P3CO) policy guidance (https://www.
phe.gov/s3/dualuse/Documents/P3CO-FinalGuidanceStatement.pdf).
The relative higher number of spike protein positive cells, and detection of icMERS-0 RNA, in epithelial cells 
of the submucosal gland at 30 dpi, in the absence of inflammatory cells, suggests the possibility that the icMERS-0 
virus may have acquired mutations that facilitate long-term viral maintenance without immune detection. An 
increased number of MERS-CoV infected cells in the submucosa agrees with previous reports demonstrating 
robust expression of the DPP4 receptor in human submucosal gland epithelia compared to little expression in 
epithelia of the conducting airways21,22. Isolation of MERS-CoV from the submucosal glands could serve as a viral 
source for subsequent adaption in the rhesus macaque. Passaging of HIV-1 in the pigtailed macaque established 
precedent for adapting viruses in monkey models23. Only 4–5 passages of HIV-1 were required to achieve an NHP 
model that recapitulated AIDS observed in humans23. Further studies would be necessary to directly confirm per-
sistence of low level MERS-CoV replication. Nonetheless, novel mutations identified by sequencing MERS-CoV 
RNA from the lungs could be incorporated into the MERS-CoV genome to generate novel infectious clones for 
subsequent passages that might yield an improved rhesus model. Moreover, a recombinant virus that produces 
disease in primates provides a strategy to evaluate virus genetic contributions to disease severity.
An NHP model that reproducibly recapitulates lethal human disease following respiratory infection may be 
effective for evaluating MERS-CoV countermeasures, but may be an oversimplification. A number of pre-existing 
conditions may contribute to an individual’s susceptibility to MERS-CoV. Increased age (>50) and several comor-
bidities (e.g. diabetes, hypertension, chronic respiratory disease, etc.) are commonly associated with individual’s that 
develop severe respiratory disease following MERS-CoV infection (reviewed in1). Capturing these complex pheno-
types in a disease model may prove difficult and not cost effective. The combination of capturing complex pheno-
types with the inability to control for host genetic variation in outbred NHP populations indicates that manipulating 
the host may prove difficult. Therefore, altering the MERS-CoV genome through adaptation may be the most feasi-
ble option for achieving a reproducible NHP model. The icMERS-0 strain demonstrates the feasibility of introduc-
ing novel genetic changes into the MERS-CoV genome that can augment respiratory disease phenotypes.
Methods
Methods to reduce study bias. Simple randomization was used to select the animals to be depopulated 
early at estimated peak disease to reduce the risk of decision bias on study outcomes. Randomization was per-
formed using the RAND function in excel to assign a number between 0 and 1 to each NHP. The animals associ-
ated with the three highest results of the RAND function were selected for sacrifice on day 5.
Virus challenge and dose quantitation. Preparation of virus inoculum and quantification of challenge 
dose MERS 0 (3T3p0, CCL-81p2) (MERS-0 in ref.2) was used for the challenge study. The ideal virus inoculum 
target was 6.7log10 PFU/mL to conform to historical studies. Virus inoculum was used undiluted as the ini-
tial virus stock titer was quantified at 6.6log10 PFU/mL average of two independent plaque assays on Vero cells 
(ATCC CCL-81).
Virus inoculum was back-titrated using the standard Avicel RC591® (FMC Biopolymer) semi-solid plaque
assay method (CS-04–45). Briefly, virus inoculum was serially diluted by half-log increments in minimal essen-
tial medium alpha (Gibco) supplemented with Anti-Anti (Gibco) and heat-inactivated 5% fetal bovine serum 
(FBS, Gibco). Three-hundred microliters of sample was assayed on near-confluent 6-well plates of Vero cells 
(ATCC CCL-81) for 1 h at 37 °C and 5% CO2 with gentle agitation every 15 minutes to prevent drying of the mon-
olayer. Following adsorption, 2 mL of a mixture of 2X eagle’s minimal essential medium (Gibco) and 2.5% Avicel 
RC591® was added to each well and plates were returned to the incubator for 3 d. Plate counts were enumerated 
after removing the overlay, staining with 0.2% gentian violet solution prepared in 10% neutral buffered formalin 
for 30 minutes, rinsing and drying the plates.
Animal studies. Six rhesus monkeys, five of whom were previously survivors of an Ebola virus study evalu-
ating efficacy of a polyclonal transgenic bovine antibody treatment, were used for this study 257 days post-Ebola 
virus infection. Animals were singly housed for the duration of the experiment and identified by both cage cards 
and tattoo markings. Animals were observed at least once daily following virus exposure. All animal experiments 
were performed in a BSL-4 laboratory, approved by the NIAID Division of Clinical Research Institutional Animal 
Care and Use Committee, and were performed in an AAALAC International accredited facility in accordance 
with relevant NIH policies and the Animal Welfare Act and Regulations.
Animals were anesthetized by immobilizing with a squeeze back cage to facilitate intramuscular delivery of 
ketamine prior to all animal handling, including physical exams and virus exposure. Virus exposure was per-
formed by using a bronchoscope to introduce flexible tubing connected to a 3-way stop cock and deposit 0.5 mL 
of inoculum from a 3cc syringe into the left bronchus. The tubing was then flushed with 6cc of air using a 12cc 
syringe to ensure delivery of the entire volume. The process was repeated to introduce an additional 0.5 mL of 
inoculum to the right bronchus.
Lung Computed Tomography Imaging and Quantitative Analysis. Animals were initially anesthe-
tized using ketamine and anesthesia was maintained by intravenous propofol. Animals were intubated to facilitate 
breath hold for image clarity. Lung field CT images were acquired using a Philips Gemini CT scanner. Image 
analysis was performed using the percent change in lung hyper-density analysis (PCLH, Solomon et al. IEEE 
27th International Symposium on Computer-Based Medical Systems) from which the hyperdensity volume as a 
percent of total lung volume was calculated by 100 × (hyperdense tissue volume/total lung volume). The analysis 
of the existing marmoset data set was performed in the same manner.
Clinical sampling. Blood was collected in clot-activated tubes containing silica beads or K3EDTA 
anti-coagulant. Clot-activated tubes were allowed to clot for at least 30 minutes prior to processing. Blood tubes 
were centrifuged at 1800 relative-centrifugal force to separate serum or plasma upstream of chemistry analysis 
was performed using the Piccolo General Chemistry 13 discs and a Piccolo xPress analyzer or complete blood 
counts using the Sysmex XS-2000VT.
Nasal swab and lung virology. Nasal swabs were collected using the BD Viral Transport system. Briefly, 
swabs were inserted into the nares and immediately transferred to the collection tubes containing virus stabili-
zation medium using sterile technique. Swabs were vortexed vigorously for 30–60 seconds. Lung tissue samples 
were collected proximal to the bronchial branches, homogenized in bead beater tubes using an OmniRuptor and 
clarified by centrifugation prior to inactivation. Supernatants were inactivated in TRIzol LS in accordance with 
manufacturer’s instructions.
RNA extraction and RT-qPCR. RNA from NHP lung aspirates was harvested in TRIzol and was iso-
lated using the Zymo Direct-zol RNA MiniPrep Kit (Zymo Research Corp., Irvine, CA, USA) according to 
the manufacturer’s directions. RNA was isolated from formalin-fixed, paraffin-embedded lung tissues using 
Qiagen’s RNeasy Formalin-Fixed Paraffin-Embedded kit according to manufacturer’s instructions (Qiagen). 
First-strand cDNA was generated using Superscript III reverse transcriptase (Life Technologies, Carlsbad, 
CA, USA). For quantification of viral genome and subgenomic RNA, real-time PCR was performed using the 
SYBR-based SsoFast EvaGreen Supermix (Bio-Rad, Hercules, CA, USA) on a Roche LightCycler 480 (Roche, 
Basel, Switzerland). Real-time reactions used primer sets that specifically detected genome RNA (ORF1) and the 
nucleocapsid-encoding subgenomic RNA (ORFN) and are listed in supplemental 4. Results were then normalized 
to Eukaryotic 18 S and analyzed using the ΔΔCt method.
Gross and Histological Pathology. All animals underwent an extensive postmortem necropsy by a qual-
ified pathologist. The animal’s overall general condition and state of major organ systems was assessed. Tissues 
trimmed to 1 cubic centimeter, submerged and fixed in 10% neutral buffered formalin for 7 days. Paraffin embed-
ded tissue sections were mounted on positively-charged slides and stained with hematoxylin and eosin prior to 
pathological examination.
Immunohistochemistry. Immunohistochemistry targeting the MERS-CoV spike protein was performed 
on lung tissue samples. Tissue slides were subjected to heat-induced antigen retrieval with a citrate based buffer 
for 30 minutes at 95 °C (Biocare Medical, Cat # DV2004) and protein blocked (Biocare Medical, Cat #BS966MM). 
Immunostaining was performed using a primary rabbit polyclonal antibody specific for MERS-CoV spike pro-
tein (Sino Biological, Cat #40069-RP02) diluted 1:1000 followed by a secondary biotinylated goat anti-rabbit IgG 
(Jackson Immunoresearch, Cat #111-065-144) at 1:1500 dilution and resolved using the VECTASTAIN Elite ABC 
HRP kit (Vector Labs, Cat #PK-6100) and Betazoid DAB Kit (Biocare Medical, Cat #BDB2004L).
Sequential double staining was carried out on formalin-fixed paraffin-embedded lung sections using goat 
polyclonal anti-CD26 (R&D Systems, Cat #AF1180) and mouse monoclonal anti-MERS CoV nucleocapsid (NP) 
protein (Biorbyt LLC, Ca t #Q11974). Protocols were completed on the Bond RX (Leica Biosystems) platform. 
Briefly, 5µm-thick sections were deparaffinized and rehydrated. Heat-induced epitope retrieval (HIER) was per-
formed using Epitope Retrieval Solution 1, pH 6.0, heated to 100 °C for 20 minutes. The specimen was then incu-
bated with hydrogen peroxide to quench endogenous peroxidase activity prior to applying the anti-CD26 at 
1:1000 for 15 minutes. Detection with DAB chromogen was completed using the Bond Polymer Refine Detection 
kit (Leica Biosystems, Cat #DS9800), with the Post Primary step being replace by an eight-minute incubation with 
rabbit anti-goat secondary antibody (Abcam, Cat #ab6740). Anti-MERS NP was then applied at 1:100 for 15 min-
utes. Fast Red detection was performed with the Bond Polymer Refine Red Detection kit (Leica Biosystems, 
Cat #DS9390), including counterstaining with hematoxylin. Slides were finally cleared through gradient alcohol 
and xylene washes prior to mounting and coverslipping. Sections were examined by a board-certified veteri-
nary pathologist (INM) using an Olympus BX51 light microscope and photomicrographs were taken using an 
Olympus DP73 camera.
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